公开(公告)号：WO2019152642A1

公开(公告)日：2019-08-08

申请号：PCT/US2019/016038

申请日：2019-01-31

Applicant: MERCK SHARP & DOHME CORP. ,  ZYMEWORKS INC.

Inventor： FAYADAT-DILMAN, Laurence ,  JUAN, Veronica ,  KHAN, Shireen ,  HUANG, Shaopeng ,  YING, Hua ,  CABRERA, Eric, Escobar ,  DESJARDINS, Genevieve

IPC: C07K16/28

CPC classification number: C07K16/2818 ,  C07K16/2803 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are anti-PD-1/LAG3 bispecific antibodies and antigen-binding fragments. Also provided here are methods and uses of these antibodies and antigen-binding fragments in the treatment of cancer or infectious disease.

公开(公告)号：WO2019140150A1

公开(公告)日：2019-07-18

申请号：PCT/US2019/013134

申请日：2019-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： CARLETON, Michael ,  FELTQUATE, David ,  DE HENAU, Olivier ,  REILLY, Timothy, Patrick ,  CHEN, Tian ,  FENG, Ye ,  HUANG, Shu-Pang, Ben ,  ZHOU, Ming ,  SURESH, Ramachandran

IPC: C07K16/24 ,  C07K16/28 ,  A61K39/395 ,  G01N33/68 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/244 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  G01N33/6869 ,  G01N2333/5421 ,  G01N2800/52

Abstract: Provided herein are methods for the clinical treatment of tumors (e.g., advanced solid tumors) in patients having certain levels of serum IL-8 using an anti-IL-8 antibody in combination with an anti-PD-1 antibody.

公开(公告)号：WO2019122884A1

公开(公告)日：2019-06-27

申请号：PCT/GB2018/053701

申请日：2018-12-19

Applicant: KYMAB LIMITED

Inventor： LABOKHA, Aksana ,  PARVEEN, Nahida ,  GALSON, Jacob ,  SAINSON, Richard Charles Alfred ,  ARKINSTALL, Stephen John

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Combinations of anti-ICOS antibodies and other drugs for immunooncology.

公开(公告)号：WO2019101347A1

公开(公告)日：2019-05-31

申请号：PCT/EP2017/080543

申请日：2017-11-27

Applicant: OSE IMMUNOTHERAPEUTICS

Inventor： COSTANTINI, Dominique

IPC: A61K39/00 ,  C07K16/00 ,  A61P35/00

CPC classification number: A61P35/00 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55566 ,  A61K2039/70 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/76 ,  A61K2300/00

Abstract: The present invention relates to improved treatment of cancer, in particular to a treatment with a composition of CTL peptides for patients after a treatment with an immune checkpoint inhibitor.

公开(公告)号：WO2019094559A2

公开(公告)日：2019-05-16

申请号：PCT/US2018/059779

申请日：2018-11-08

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： FAUSTMAN, Denise, L.

CPC classification number: C07K16/2878 ,  A61K2039/505 ,  A61K2039/507 ,  A61P31/06 ,  A61P31/18 ,  A61P35/00 ,  C07K16/24 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T- regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.

公开(公告)号：WO2019070497A1

公开(公告)日：2019-04-11

申请号：PCT/US2018/053066

申请日：2018-09-27

Applicant: IMCLONE LLC

Inventor： GAYNOR, Richard Brian ,  ILARIA, Robert Leslie

IPC: A61K39/395 ,  A61P35/00

CPC classification number: A61P35/00 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2818 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/76

Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating soft tissue sarcoma, comprising administering olaratumab and pembrolizumab to a subject in need thereof.

公开(公告)号：WO2019059411A1

公开(公告)日：2019-03-28

申请号：PCT/JP2018/036161

申请日：2018-09-19

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA ,  F. HOFFMANN-LA ROCHE AG

Inventor： OHTOMO, Toshihiko ,  TANAKA, Takayoshi ,  NAKAMURA, Mikiko

IPC: A61K45/06 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61P35/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/836 ,  A61K2039/844 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/303 ,  C07K2317/24 ,  C07K2317/94

Abstract: Provided are dosage regimens for combination therapy using PD-1 axis binding antagonists and GPC3 targeting agent. For example, the dosage regimens comprise (i) a loading period within which the GPC3 targeting agent is administered, followed by (ii) a maintenance period within which the PD-1 axis binding antagonist and the GPC3 targeting agent are administered.

公开(公告)号：WO2019006003A1

公开(公告)日：2019-01-03

申请号：PCT/US2018/039817

申请日：2018-06-27

Applicant: THE TRUSTEES OF PRINCETON UNIVERSITY

Inventor： RABINOWITZ, Joshua, D.

IPC: A61K31/19 ,  A61K45/06 ,  A61K31/14 ,  A61K31/198 ,  A61K31/205 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/519 ,  A61K31/7004 ,  C12N15/113 ,  A61P35/00 ,  A61K39/00 ,  A61K35/17 ,  C12N5/0783 ,  A61K39/395

CPC classification number: A61K31/19 ,  A61K31/14 ,  A61K31/198 ,  A61K31/205 ,  A61K31/405 ,  A61K31/4172 ,  A61K31/519 ,  A61K31/7004 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/545 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3084 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/0636 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2500/02 ,  C12N2501/71 ,  C12N2501/999 ,  A61K2300/00

Abstract: The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to a subject a population of immune cells that express an exogenous enzyme that facilitates immune cell function in a nutrient-poor environment. Other embodiments of the invention include methods of promoting an immune response to a tumor in a subject in need thereof, comprising administering to the subject an effective amount of an agent that provides a one-carbon unit (e.g., formate) and an agent that promotes an anti-tumor response, and methods of promoting an immune response to a tumor in a subject in need thereof, comprising administering to a subject an effective amount of an agent that inhibits consumption of metabolic fuels by tumor cells. The invention also provides, in other embodiments, compositions comprising an ex vivo population of immune cells expressing an exogenous enzyme that enhances immune cell function in nutrient poor environments, and compositions comprising a nucleic acid expression construct encoding an inhibitor of glucose metabolism, and a pharmaceutically acceptable carrier or excipient.

公开(公告)号：WO2018204760A1

公开(公告)日：2018-11-08

申请号：PCT/US2018/031049

申请日：2018-05-04

Applicant: WEINER, David ,  MUTHUMANI, Kar ,  DUPERRET, Elizabeth ,  WISE, Megan

Inventor： WEINER, David ,  MUTHUMANI, Kar ,  DUPERRET, Elizabeth ,  WISE, Megan

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/001157 ,  A61K39/3955 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/585 ,  A61P35/00 ,  C07K16/2866 ,  A61K2300/00

Abstract: Disclosed herein is an immunogenic composition comprising at least an antigen and CTLA4 antibody. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the immunogenic composition to the subject in need thereof.

公开(公告)号：WO2018068756A1

公开(公告)日：2018-04-19

申请号：PCT/CN2017/106024

申请日：2017-10-13

Applicant: BEIJING BIOCYTOGEN CO., LTD

Inventor： SHEN, Yuelei ,  BAI, Yang ,  GUO, Yanan ,  HUANG, Rui ,  ZHOU, Xiaofei ,  ZHANG, Meiling

IPC: C12N15/85 ,  C12N15/90 ,  C12N15/113 ,  C07K14/705 ,  C12N15/12 ,  A01K67/027 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61P35/00 ,  A01K67/027 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2319/00 ,  C12N15/1138 ,  C12N15/85 ,  C12N15/90 ,  C12N2310/20

Abstract: Genetically modified non-human animals that express a human or chimeric (e.g., humanized) B-and T-Lymphocyte-Associated Protein (BTLA or CD272), and methods of use thereof are provided.

Abstract translation: 提供表达人或嵌合（例如，人源化）B和T淋巴细胞相关蛋白（BTLA或CD272）的基因修饰的非人动物及其使用方法。 p>